MOB015B vehicle

DRUG3 trials

Sponsors

Moberg Pharma AB

Conditions

Distal Subungual OnychomycosisErythema

Phase 1

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

CompletedNCT06369727

Moberg Pharma ABErythema

Start: 2017-10-15End: 2018-02-15Updated: 2024-04-17

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

CompletedNCT06369675

Moberg Pharma ABErythema

Start: 2017-10-19End: 2017-11-14Updated: 2024-04-17

Phase 3

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

CompletedNCT02859519

Moberg Pharma ABDistal Subungual Onychomycosis

Start: 2016-10-31End: 2019-11-13Updated: 2020-12-24